Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2021
• Auteurs : Virginie CarmignacCyril MignotEmmanuelle BlanchardPaul KuentzMarie-Hélène Aubriot-LortonVictoria E.R. ParkerArthur SorlinSylvie FraitagJean-Benoît CourcetYannis DuffourdDiana RodriguezRachel KnoxSatyamaanasa PolubothuAnne BolandRobert OlasoMarc DelepineVéronique DarmencyMelissa RiachiChloé QuelinPaul RollierLouise GoujonSarah GrottoYline CapriMarie-Line JacquemontSylvie OdentDaniel AmramMartin ChevarinCatherine Vincent-DelormeBenoît CatteauLaurent GuibaudAlexis ArzimanoglouMalika KeddarCatherine SarretPatrick CallierDidier BessisDavid GenevièveJean‐françois DeleuzeChristel Thauvin-RobinetRobert SempleChristophe PhilippeJean-Baptiste RivièreVeronica KinslerLaurence FaivrePierre Vabres
• Organismes : Institut Pascal
• Publié dans Genetics in Medicine le 25/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2021
• Auteurs : Sydney DuboisPhilippe RuminyElodie BohersPierre‐julien ViaillyLiana VeresezanJean‐michel PicquenotVictor BobéeMathieu ViennotDominique PentherVincent CamusCatherine ThieblemontCamille PouatyHervé TillyFabrice Jardin
• Organismes : Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Hopital Saint-Louis [AP-HP] Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen
• Publié dans Clinical Case Reports le 01/11/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2021
• Auteurs : Alexandre GodonCharles Ambroise TacquardAlexandre MansourDelphine GarriguePhilippe NguyenDominique LasneSophie TestaJerrold LevyPierre AlbaladejoYves GruelSophie SusenAnne GodierPierre AlbaladejoN. BlaisF. BonhommeAnnie Borel-DerlonAriel CohenJ.-P. ColletE. de MaistreP. FontanaD. Garrigue HuetAnne GodierYves GruelAlexandre GodonB. IckxSilvy LaporteDominique LasneJ. LlauG. Le GalT. LecompteS. LessireJ.H. LevyD. LongroisS. Madi-JebaraAlexandre MansourM. MazighiPatrick MismettiP.E. MorangeS. MotteF. MullierN. NathanPhilippe NguyenGilles PernodN. RosencherS. RoulletP.M. RoyS. SchlumbergerP. SiéA. SteibSophie SusenC.A. TacquardSophie TestaA. VincentelliP. ZuffereyA. Borel-DerlonE BoissierB DumontE. de MaistreYves GruelC JamesDominique LasneT. LecompteP.E. MorangePhilippe NguyenP. SiéVirginie SiguretSophie Susen
• Organismes : BrainTech Laboratory [CHU Grenoble Alpes - Inserm U1205] Hôpitaux Universitaires de Strasbourg Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre Hospitalier Régional Universitaire [CHU Lille] Hôpital universitaire Robert Debré [Reims] Hôpital Necker - Enfants Malades [AP-HP] Istituti Ospitalieri di Cremona Duke University [Durham] Centre Hospitalier Universitaire [CHU Grenoble] CHU Trousseau [Tours] Centre Hospitalier Régional Universitaire [CHU Lille] Hôpital Européen Georges Pompidou [APHP] Centre Hospitalier Universitaire [CHU Grenoble] Institut des Sciences de l'Evolution de Montpellier Association française des hémophiles Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases CHU Saint-Antoine [AP-HP] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Institut de cardiologie [CHU Pitié-Salpêtrière] CHU Dijon Federal Institute for Materials Research and Testing - Bundesanstalt für Materialforschung und -prüfung Hôpital Européen Georges Pompidou [APHP] CHU Trousseau [Tours] BrainTech Laboratory [CHU Grenoble Alpes - Inserm U1205] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Santé Ingénierie Biologie Saint-Etienne Hémostase, Inflammation, Thrombose Groupe d'Etude de la Thrombose de Bretagne Occidentale Hôpitaux Universitaires de Genève = University Hospital of Geneva [Genève] Université de Genève = University of Geneva CHU UCL Namur AP-HP - Hôpital Bichat - Claude Bernard [Paris] Université Paris Cité Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Fondation Ophtalmologique Adolphe de Rothschild [Paris] Laboratoire de Recherche Vasculaire Translationnelle Hôpital Lariboisière-Fernand-Widal [APHP] FHU NeuroVasc [Site Sainte-Anne, Paris] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] F-Crin INvestigation Network On Venous Thrombo-Embolism [CHU Saint-Etienne] Santé Ingénierie Biologie Saint-Etienne CHU UCL Namur CHU Trousseau [APHP] Maladies génétiques d'expression pédiatrique Hôpital universitaire Robert Debré [Reims] Université Grenoble Alpes - UFR Médecine Service d'anesthésie-réanimation [Hôtel-Dieu] Université de Bordeaux Centre Hospitalier Universitaire de Toulouse Exail (iXblue) Centre Hospitalier Régional Universitaire [CHU Lille] Santé Ingénierie Biologie Saint-Etienne Association française des hémophiles CHU Dijon CHU Trousseau [Tours] Hôpital universitaire Robert Debré [Reims] Service d’Hématologie Biologique [CHU Lariboisière] Innovations thérapeutiques en hémostase = Innovative Therapies in Haemostasis Centre Hospitalier Régional Universitaire [CHU Lille]
• Publié dans Anaesthesia Critical Care & Pain Medicine le 27/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2021
• Auteurs : Pascal RoulletGuillaume VaivaEtienne VéryAxel BourcierAntoine YrondiLaetitia DupuchPierre LamyClaire ThalamasLaurence JasseWissam El-HagePhilippe Birmes
• Organismes : Université Toulouse III - Paul Sabatier Centre expert stress traumatique [CHU Toulouse] Centre Hospitalier Régional Universitaire [CHU Lille] Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 Toulouse NeuroImaging Center Centre Hospitalier Universitaire de Toulouse Toulouse NeuroImaging Center Centre expert stress traumatique [CHU Toulouse] Centre Hospitalier Universitaire de Toulouse Centre d'investigation clinique de Toulouse Centre d'investigation clinique de Toulouse Imaging, Brain & Neuropsychiatry Centre d’Investigation Clinique [Tours] CIC 1415 Toulouse NeuroImaging Center Centre expert stress traumatique [CHU Toulouse]
• Publié dans Neuropsychopharmacology le 01/11/2020

---

Résumé : Post-traumatic stress disorder (PTSD) is difficult to treat but one promising strategy is to block memory reconsolidation of the traumatic event. This study aimed to evaluate the efficacy of traumatic memory reactivation under the influence of propranolol, a noradrenergic beta-receptor blocker, in reducing PTSD symptoms as well as comorbid major depression (MD) symptoms. We conducted a double blind, placebo-controlled, randomised clinical trial in 66 adults diagnosed with longstanding PTSD. Propranolol or a placebo was administered 90 min before a brief memory reactivation session, once a week for 6 consecutive weeks. Measures included the SCID PTSD module, the PTSD Check List (PCL-S) and the Beck Depression Inventory-II (BDI-II). PTSD symptoms decreased both in the pre-reactivation propranolol group (39.28%) and the pre-reactivation placebo group (34.48 %). During the 6 treatment sessions, PCL-S and BDI-II scores decreased to similar extent in both groups and there were no treatment differences. During the 3-month follow-up period, there were no treatment effects for the mean PCL-S and BDI-II scores. However, in patients with severe PTSD symptoms (PCL-S ≥ 65) before treatment, PCL-S and BDI-II scores continued to decline 3 months after the end of treatment in the propranolol group while they increased in the placebo group. Repeated traumatic memory reactivation seemed to be effective for PTSD and comorbid MD symptoms. However, the efficacy of propranolol was not greater than that of placebo 1 week post treatment. Furthermore, in this traumatic memory reactivation, PTSD symptom severity at baseline might have influenced the post-treatment effect of propranolol.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2021
• Auteurs : Joris GallandBenjamin ThoreauMaxime DelrueMarie NeuwirthAlain StepanianAnthony ChauvinAzeddine DellalOlivier NalletMelanie RorizMathilde DevauxJonathan LondonGonzague Martin-LecampAntoine FroissartNouara ArabBertrand FerronMarie‐helene GroffViviane QueyrelChristine LorutLucile RegardEmilie BerthouxGuillaume BayerCloé ComarmondBertrand LiogerArsène MékinianTali‐anne SzwebelThomas SenéBlanca Amador-BoreiroOlivier ManginPierre‐olivier SellierStephane MoulyJean‐philippe KevorkianVirginie SiguretDominique VodovarDamien SèneAlbertini MathieuBouajila SaraBritany KimbimbiBurlacu RuxandraCacoub LéaChampion KarineDelcey VéroniqueDillinger Jean-GuillaumeFeron FlorineFrazier AlineThomas Funck-BretanoGauthier Diane-CecileGautier Jean-FrançoisHenry PatrickHuscenot TessaSarah IzabelMathilde JaulerryJouabli MoenesJulla Jean-BaptisteLaloi Michelin MarieLeroy PierreLopes AmandaBruno MégarbaneMichon MaximeMunier Anne-LiseNahmani YoramNicol MartinNicolas EroanPoulat AudreyRevue EricRichette PascalRiveline Jean-PierreRubenstein EmmaZanin AdrienAveneau ClémentBastard PaulBeauvais DianeBoghez LoredanaBorderiou AlixConway PaulCosma LavigniaDavy VincentDesjardin ClémentDevatine SandraDucroz Gerardin ChristelDupe CharlotteGobert ChloéGros ClotildeKadiri SoumayaKhan EnmatOngnessek SandrineRhmari FatimaSacco IsabelleSaptefrat NataliaSchaupp PaulineJustine SerreSideris GeorgiosSmati SoniaTournier MarineTreca PaulineTruong TonyTuffier MathildeArcelli MattéoBoue YvonnickCopie AlbanDeye NicolasEkherian Jean-MichelErrabih ZaccariaGonde AntoineGrant CarolineGuerin EmmanuelleMagalhaes AdèleMalissin IsabelleMeurisse EdouardMrad AymenNaim GiuliaNguyen PhilippeNitenberg KiyokoPepin‐lehalleur AdrienPerault ArthurPerrin LucileRenaud MaximeSutterlin LaetitiaDelrue MaximeSiguret VirginieStepanian Alain
• Organismes : Hôpital Lariboisière-Fernand-Widal [APHP] CHU Trousseau [Tours] Service d’Hématologie Biologique [CHU Lariboisière] Recherche clinique appliquée à l'hématologie Service de Réanimation Médicale et Toxicologique [Hôpital Lariboisière] Optimisation thérapeutique en Neuropsychopharmacologie Hôpital Lariboisière-Fernand-Widal [APHP] Recherche clinique appliquée à l'hématologie Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB) Groupe Hospitalier Intercommunal Le Raincy-Montfermeil Groupe Hospitalier Intercommunal Le Raincy-Montfermeil Centre Hospitalier Régional Universitaire de Tours Service de Médecine Interne [CHI Poissy-Saint-Germain] Institut Cochin Centre hospitalier de Pau Centre Hospitalier Intercommunal de Créteil Centre Hospitalier Intercommunal de Créteil Centre hospitalier de Sens Service Rhumatologie [CHU Nice] Centre de compétence des maladies auto-immunes systémiques rares Service de pneumologie [CHU Cochin] Service de pneumologie [CHU Cochin] Centre hospitalier Saint Joseph - Saint Luc [Lyon]
• Publié dans European Journal of Haematology le 22/10/2020

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 01/08/2021
• Auteurs : Mira IbrahimPhilippe GuibertKhanh-Hung Tran
• Organismes : Institut Jean Le Rond d'Alembert Institut Jean Le Rond d'Alembert Laboratoire Energétique Mécanique Electromagnétisme

---

Résumé : Homogeneous Charge Compression Ignition (HCCI) is an innovative strategy to reduce pollutant emissions at the source. In order to control lean combustion ignition, various approaches can be applied. In this work, we propose to control the ignition of reactive biogas mixtures by direct injection of biomass powder. Thus, a particle injector was integrated into an RCM (Rapid Compression Machine) chamber, allowing the study of diphasic gas/solid combustion. The preliminary tests were applied to different biogas mixtures of CH4, CO2, and H2 having particularly interesting properties. The study highlights the advantages of using biomass mixtures with lean homogeneous combustion. The results were satisfyingly reproducible, highlighting the benefits of injected particles in controlling the ignition timing of HCCI engines.

---

Fichiers liés : conferencepaper.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2021
• Auteurs : Jens KammererSylvestre LacourTomas StolkerPaul MolliereDavid K SingEvert NasedkinPierre KervellaJason J WangKimberly Ward-DuongMichael NowakRoberto AbuterAntonio AmorimRuben Asensio-TorresMichi BauböckMyriam BenistyJean-Philippe BergerHervé BeustS. BluntAnthony BoccalettiA. BohnMari-Lena BolzerMickaël BonnefoyHenri BonnetW. BrandnerFaustine CantalloubePaola CaselliBenjamin CharnayGaël ChauvinElodie ChoquetValentin ChristiaensYann ClénetVincent Coudé Du ForestoAlex CridlandRoderick DembetJ. DexterTim de ZeeuwAntonia DrescherGilles DuvertAndreas EckartFrank EisenhauerFei GaoP. GarciaR. Garcia LopezÉric GendronReinhard GenzelS. GillessenJulien H. GirardXavier HauboisG. HeisselThomas HenningSasha HinkleyS. HipplerM. HorrobinMathis HoulléZ. HubertLaurent JocouM. KepplerLaura KreidbergA.-M. LagrangeV. LapeyrèreJean-Baptiste Le BouquinP. LénaDieter LutzA.-L. MaireAntoine MérandJohn MonnierD. MouilletA. MüllerT. OttGilles OttenC. PaladiniThibaut PaumardK. PerrautS. A. WiederkehrO. PfuhlL. PueyoJulien RameauL. RodetG. RoussetZ. RustamkulovJinyi ShangguanT. Taro ShimizuJ. StadlerO. StraubC. StraubmeierE. SturmLinda TacconiEwine Van dishoeckArthur ViganF. VincentS. von FellenbergF. WidmannE. WieprechtE. WiezorrekJulien WoillezSenol Yazici
• Organismes : European Southern Observatory Research School of Astronomy and Astrophysics [Canberra] Space Telescope Science Institute Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics European Southern Observatory Leiden Observatory [Leiden] Max Planck Institute for Astronomy Department of Physics and Astronomy [Baltimore] Morton K. Blaustein Department of Earth and Planetary Sciences [Baltimore] Max Planck Institute for Astronomy Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Caltech Department of Astronomy [Pasadena] Space Telescope Science Institute Institute of Astronomy [Cambridge] European Southern Observatory Centro de Astrofísica e Gravitação [Instituto Superior Técnico, Lisboa] = Center for Astrophysics and Gravitation [Lisbon] Max Planck Institute for Astronomy Max Planck Institute for Extraterrestrial Physics Institut de Planétologie et d'Astrophysique de Grenoble Institut de Planétologie et d'Astrophysique de Grenoble Institut de Planétologie et d'Astrophysique de Grenoble Caltech Department of Astronomy [Pasadena] Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Leiden Observatory [Leiden] Max Planck Institute for Extraterrestrial Physics Institut de Planétologie et d'Astrophysique de Grenoble European Southern Observatory Max Planck Institute for Astronomy Max Planck Institute for Astronomy Max Planck Institute for Extraterrestrial Physics Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Institut de Planétologie et d'Astrophysique de Grenoble Laboratoire d'Astrophysique de Marseille Monash University [Clayton] Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Leiden Observatory [Leiden] European Southern Observatory Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics University of Colorado [Boulder] Leiden Observatory [Leiden] Max Planck Institute for Extraterrestrial Physics Max Planck Institute for Extraterrestrial Physics Institut de Planétologie et d'Astrophysique de Grenoble Universität zu Köln = University of Cologne Max Planck Institute for Radio Astronomy Max Planck Institute for Extraterrestrial Physics Hamburger Sternwarte/Hamburg Observatory Centro de Astrofísica e Gravitação [Instituto Superior Técnico, Lisboa] = Center for Astrophysics and Gravitation [Lisbon] Universidade do Porto = University of Porto Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Institut de Planétologie et d'Astrophysique de Grenoble Institut de Planétologie et d'Astrophysique de Grenoble Institut de Planétologie et d'Astrophysique de Grenoble Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Institut de Planétologie et d'Astrophysique de Grenoble Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Institut de Planétologie et d'Astrophysique de Grenoble Laboratoire d'Astrophysique de Marseille Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Institut de Planétologie et d'Astrophysique de Grenoble Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Institut de Planétologie et d'Astrophysique de Grenoble Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Laboratoire d'Astrophysique de Marseille Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics
• Publié dans Astronomy & Astrophysics - A&A le 28/10/2020

---

Résumé : Context. Near-infrared interferometry has become a powerful tool for studying the orbital and atmospheric parameters of substellar companions. Aims. We aim to reveal the nature of the reddest known substellar companion HD 206893 B by studying its near-infrared colors and spectral morphology and by investigating its orbital motion. Methods. We fit atmospheric models for giant planets and brown dwarfs and perform spectral retrievals with petitRADTRANS and ATMO on the observed GRAVITY, SPHERE, and GPI spectra of HD 206893 B. To recover its unusual spectral features, first and foremost its extremely red near-infrared color, we include additional extinction by high-altitude dust clouds made of enstatite grains in the atmospheric model fits. However, forsterite, corundum, and iron grains predict similar extinction curves for the grain sizes considered here. We also infer the orbital parameters of HD 206893 B by combining the ~100 μas precision astrometry from GRAVITY with data from the literature and constrain the mass and position of HD 206893 C based on the Gaia proper motion anomaly of the system. Results. The extremely red color and the very shallow 1.4 μm water absorption feature of HD 206893 B can be fit well with the adapted atmospheric models and spectral retrievals. By comparison with AMES-Cond evolutionary tracks, we find that only some atmosphericmodels predict physically plausible objects. Altogether, our analysis suggests an age of ~ 3–300 Myr and a mass of ~ 5–30 M Jup for HD 206893 B, which is consistent with previous estimates but extends the parameter space to younger and lower-mass objects. The GRAVITY astrometry points to an eccentric orbit ( e = 0.29 −0.11 +0.06 ) with a mutual inclination of <34.4 deg with respectto the debris disk of the system. Conclusions. While HD 206893 B could in principle be a planetary-mass companion, this possibility hinges on the unknown influence of the inner companion on the mass estimate of 10 −4 +5 M Jup from radial velocity and Gaia as well as a relatively small but significant Argus moving group membership probability of ~ 61%. However, we find that if the mass of HD 206893 B is <30 M Jup , then the inner companion HD 206893 C should have a mass between ~ 8–15 M Jup . Finally, further spectroscopic or photometric observations at higher signal-to-noise and longer wavelengths are required to learn more about the composition and dust cloud properties of HD 206893 B.

---

Fichiers liés : aa40749-21.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2021
• Auteurs : Jean Philippe HerbeuvalClaude LambertOdile SabidoMichèle CottierPierre FournelMichel DyChristian Genin
• Organismes : Institut National de la Santé et de la Recherche Médicale
• Publié dans Cytokine le 31/10/2020

---

Résumé : Type I interferons are essential for host response to viral infections, while dysregulation of their response can result in autoinflammation or autoimmunity. Among IFNα (alpha) responses, 13 subtypes exist that signal through the same receptor, but have been reported to have different effector functions. However, the lack of available tools for discriminating these closely related subtypes, in particular at the protein level, has restricted the study of their differential roles in disease. We developed a digital ELISA with specificity and high sensitivity for the IFNα2 subtype. Application of this assay, in parallel with our previously described pan-IFNα assay, allowed us to study different IFNα protein responses following cellular stimulation and in diverse patient cohorts. We observed different ratios of IFNα protein responses between viral infection and autoimmune patients. This analysis also revealed a small percentage of autoimmune patients with high IFNα2 protein measurements but low pan-IFNα measurements. Correlation with an ISG score and functional activity showed that in this small sub group of patients, IFNα2 protein measurements did not reflect its biological activity. This unusual phenotype was partly explained by the presence of anti-IFNα auto-antibodies in a subset of autoimmune patients. This study reports ultrasensitive assays for the study of IFNα proteins in patient samples and highlights the insights that can be obtained from the use of multiple phenotypic readouts in translational and clinical studies.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2021
• Auteurs : Guillaume LebretonMatthieu SchmidtMaharajah PonnaiahThierry FolliguetMarylou ParaJulien GuihaireEmmanuel LansacÉdouard SageBernard CholleyBruno MégarbanePierrick CronierJonathan ZarkaDaniel da SilvaSebastien BessetTristan Morichau-BeauchantIgor LacombatNicolas MongardonChristian RichardJacques DuranteauCharles CerfGabriel SaiydounRomain SonnevilleJean-Daniel ChichePatrick NatafDan LongroisAlain CombesPascal LeprinceCharles JuvinThibault SchoellCosimo d'AlessandroSofica MarinNathalie NardonePierre DemondionHoracio MeyerKarl BounaderAlexander Moiroux-SahraouiAli AkamkamGuillaume FadelErwan RandrianalisoaSébastien CusquelPatrice Le GloahecElisabeth HirschauerFabrice MusquetPierre-Marie JegoHélène GuedesThéophile RoyLina MercereauEmmanuel CorvolAnne LaboureFlore VilanoveMarco PeperoniDariène MachadoAly SelyMarion FortanierSéverine GantoisEmilie TranElisabeth BosqAurélie FontanierAlice MorinJocelyne CousinStéphanie BovagnetCharles-Edouard LuytGuillaume HékimianNicolas BréchotMarc Pineton de ChambrunCyrielle DesnosJuliette ChomelouxJeremy ArzoineEmmanuelle GuerinAntoine MonselGuillaume VoiriotDavid LevyElodie BaronAlexandra BeurtonJuliette ChommelouxMeng ParisSafaa NemlaghiPierre BayAlexandre DemouleBertrand GuidetJean Michel ConstantinMuriel FartoukhMartin DresPatrick NatafGuillaume FranchineauLucie Le FevreRichard RaffoulSoleiman AlkhoderWalid GhodbaneAngelo PisaniWael BrahamAli Bessem GaraPierre MordantYves-Hervé CastierEtienne de MontmollinLila BouadmaJean-François TimsitOlivier LangeronQuentin de RouxClaire AlessandriMargot Arminot-FrémauxSimon ClariotThomas DessalleAgathe KudelaAndré LyArnaud MeffertElena SkripkinaAntonio FioreCostin RaduEleonora Dupuy-MontbrunChristian LatremouilleOlaf MercierPhilippe DeleuzeFrançois StephanJacques DuranteauChristian RichardMarie WernerJean-Louis TeboulXavier MonnetHassan DebbaghAlain ChapelierJulien de WolfMatthieu GlorionCiprian PricopiFrancesco CassianoSébastien JacqueminGuillaume TachonFrançois ParquinBenjamin ZuberAlain CarriouJean-Paul MiraJulien CharpentierFrederic PeneLee NguyenSébastian VoicuNicolas DeyeIsabelle MalissinLaetitia SutterlinGiulia NaimAdrien Pépin-LehalleurAymen MradJean-Michel EkhérianPhilippe NguyenGeorgios SidérisDominique VodovarCaroline GrantMattéo ArcelliAlban CopieZaccaria ErrabihAntoine GondeAdèle MagalhaesEdouard MeurisseKiyoko NitenbergArthur PeraultLucile PerrinMaxime RenauxSophie MarquéLuis Ensenyat-MartinEric DelpierreMatthieu DupreyDaniel da SilvaBruno VerdièreJulien AmourMarina ClémentYves OllivierTristan Morichau-BeauchantFabrice DaviaudCamille Le BretonSantiago Freita-RamosMarc AmourettiPierre Antoine BillietMyriam DaoLouis Marie DumontLaura FedericiBaptiste GaborieauPierre Postel-VinayConstance VuillardNoémie ZucmanDidier DreyfussJean Damien RicardDamien Roux
• Organismes : CHU Pitié-Salpêtrière [AP-HP] Institut de cardiologie [CHU Pitié-Salpêtrière] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Hôpital Henri Mondor Molecular virology and immunology – Physiopathology and therapeutic of chronic viral hepatitis (Team 18) AP-HP - Hôpital Bichat - Claude Bernard [Paris] Hôpital Marie-Lannelongue Institut Mutualiste de Montsouris Hôpital Foch [Suresnes] Hôpital Foch [Suresnes] Université Paris Cité Hôpital Européen Georges Pompidou [APHP] Service de Réanimation Médicale et Toxicologique [Hôpital Lariboisière] Optimisation thérapeutique en Neuropsychopharmacologie Centre Hospitalier Sud Francilien Grand Hôpital de l'Est Francilien Hôpital Delafontaine Laboratoire de Tribologie et Dynamique des Systèmes Centre cardiologique du Nord Hôpital Privé Jacques Cartier [Massy] CHU Henri Mondor [Créteil] Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Hôpitaux Universitaires Paris Sud [AP-HP] Université Paris-Sud - Paris 11 Hôpital Foch [Suresnes] Service de Réanimation Médicale, Hôpital Foch Hôpital Henri Mondor
• Publié dans The Lancet Respiratory Medicine le 23/10/2020

---

Résumé : Background: In the Île-de-France region (henceforth termed Greater Paris), extracorporeal membrane oxygenation (ECMO) for severe acute respiratory distress syndrome (ARDS) was considered early in the COVID-19 pandemic. We report ECMO network organisation and outcomes during the first wave of the pandemic.Methods: In this multicentre cohort study, we present an analysis of all adult patients with laboratory-confirmed SARS-CoV-2 infection and severe ARDS requiring ECMO who were admitted to 17 Greater Paris intensive care units between March 8 and June 3, 2020. Central regulation for ECMO indications and pooling of resources were organised for the Greater Paris intensive care units, with six mobile ECMO teams available for the region. Details of complications (including ECMO-related complications, renal replacement therapy, and pulmonary embolism), clinical outcomes, survival status at 90 days after ECMO initiation, and causes of death are reported. Multivariable analysis was used to identify pre-ECMO variables independently associated with 90-day survival after ECMO.Findings: The 302 patients included who underwent ECMO had a median age of 52 years (IQR 45-58) and Simplified Acute Physiology Score-II of 40 (31-56), and 235 (78%) of whom were men. 165 (55%) were transferred after cannulation by a mobile ECMO team. Before ECMO, 285 (94%) patients were prone positioned, median driving pressure was 18 cm H2O (14-21), and median ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen was 61 mm Hg (IQR 54-70). During ECMO, 115 (43%) of 270 patients had a major bleeding event, 27 of whom had intracranial haemorrhage; 130 (43%) of 301 patients received renal replacement therapy; and 53 (18%) of 294 had a pulmonary embolism. 138 (46%) patients were alive 90 days after ECMO. The most common causes of death were multiorgan failure (53 [18%] patients) and septic shock (47 [16%] patients). Shorter time between intubation and ECMO (odds ratio 0·91 [95% CI 0·84-0·99] per day decrease), younger age (2·89 [1·41-5·93] for ≤48 years and 2·01 [1·01-3·99] for 49-56 years vs ≥57 years), lower pre-ECMO renal component of the Sequential Organ Failure Assessment score (0·67, 0·55-0·83 per point increase), and treatment in centres managing at least 30 venovenous ECMO cases annually (2·98 [1·46-6·04]) were independently associated with improved 90-day survival. There was no significant difference in survival between patients who had mobile and on-site ECMO initiation.Interpretation: Beyond associations with similar factors to those reported on ECMO for non-COVID-19 ARDS, 90-day survival among ECMO-assisted patients with COVID-19 was strongly associated with a centre's experience in venovenous ECMO during the previous year. Early ECMO management in centres with a high venovenous ECMO case volume should be advocated, by applying centralisation and regulation of ECMO indications, which should also help to prevent a shortage of resources.

---

Fichiers liés : main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2021
• Auteurs : François ZhuWagih Ben HassenNicolas BricoutBasile KerlerouxKevin JanotBenjamin GoryRené AnxionnatSébastien RichardAdrien MarchalRaphael BlancMichel PiotinArturo ConsoliDenis TrystramChristine Rodriguez RegentJean-Philippe DesillesDavid Weisenburger-LileSimon EscalardDenis HerbreteauHeloise IferganIgor Lima MaldonadoJulien LabreucheHilde HenonOlivier NaggaraBertrand LapergueGrégoire Boulouis
• Organismes : Imagerie Adaptative Diagnostique et Interventionnelle Département de neuroradiologie diagnostique et thérapeutique [CHRU Nancy] Institut de psychiatrie et neurosciences de Paris Departement de Neuroradiologie [Lille] Institut de psychiatrie et neurosciences de Paris Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Régional Universitaire de Tours Imagerie Adaptative Diagnostique et Interventionnelle Département de neuroradiologie diagnostique et thérapeutique [CHRU Nancy] Imagerie Adaptative Diagnostique et Interventionnelle Département de neuroradiologie diagnostique et thérapeutique [CHRU Nancy] Défaillance Cardiovasculaire Aiguë et Chronique Service de neurologie [CHRU Nancy] Centre Hospitalier Régional Universitaire [CHU Lille] Fondation Ophtalmologique Adolphe de Rothschild [Paris] Fondation Ophtalmologique Adolphe de Rothschild [Paris] Hôpital Foch [Suresnes] Institut de psychiatrie et neurosciences de Paris Institut de psychiatrie et neurosciences de Paris Fondation Ophtalmologique Adolphe de Rothschild [Paris] Hôpital Foch [Suresnes] Fondation Ophtalmologique Adolphe de Rothschild [Paris] Centre Hospitalier Régional Universitaire de Tours Université de Tours Centre Hospitalier Régional Universitaire de Tours Imaging, Brain & Neuropsychiatry Evaluation des technologies de santé et des pratiques médicales - ULR 2694 Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 Département de neurologie [Lille] Institut de psychiatrie et neurosciences de Paris Hôpital Foch [Suresnes] Institut de psychiatrie et neurosciences de Paris Imaging, Brain & Neuropsychiatry
• Publié dans Stroke le 31/10/2020

---

Résumé : Background and Purpose: We aimed to evaluate among trained interventional neuroradiologist, whether increasing individual experience was associated with an improvement in mechanical thrombectomy (MT) procedural performance metrics. Methods: Individual MT procedural data from 5 centers of the Endovascular Treatment in Ischemic Stroke registry and 2 additional high-volume stroke centers were pooled. Operator experience was defined for each operator as a continuous variable, cumulating the number of MT procedures performed since January 2015, as MT became standard of care or, if later than this date, since the operator started performing mechanical thrombectomies in autonomy. We tested the associations between operator’s experience and procedural metrics. Results: A total of 4516 procedures were included, performed by 36 operators at 7 distinct centers, with a median of 97.5 endovascular treatment procedures per operator (interquartile range, 57–170.2) over the study period. Higher operator’s experience, analyzed as a continuous variable, was associated with a significantly shorter procedural duration (β estimate, −3.98 [95% CI, −5.1 to −2.8]; P<0.001), along with local anesthesia and M1 occlusion location in multivariable models. Increasing experience was associated with better Thrombolysis in Cerebral Infarction scores (estimate, 1.02 [1–1.04]; P=0.013). Conclusions: In trained interventional neuroradiologists, increasing experience in MT is associated with significantly shorter procedural duration and better reperfusion rates, with a theoretical ceiling effect observed after around 100 procedures. These results may inform future training and practice guidelines to set minimal experience standards before autonomization, and to set-up operators’ recertification processes tailored to individual case volume and prior experience.

---

Source